Masitinib Slows Disability Progression in PPMS and Non-active SPMS, Phase 2/3 Trial Reports

26 February 2020

Source Multiple Sclerosis News Today: AB Science‘s masitinib significantly slowed disability progression in people with primary progressive multiple sclerosis (PPMS) and non-active secondary progressive MS (SPMS) at a lower dose of 4.5 mg/kg a day, top-line results from a Phase 2b/3 clinical trial show.

Masitinib, formerly known as AB1010, is an oral therapy that inhibits the activity of cells in the innate immune system, specifically mast cells, microglia, and macrophages. In doing so, the therapy is expected to limit the inflammatory processes that cause damage to the nervous system in MS.

It may also have applications in other conditions, including other neurological diseases and certain cancers.  Read on.

Blog categories: 

Category

Archive